(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 921MM | -11% |
Gross Profit | 561.9MM | -14% |
Cost Of Revenue | 359.1MM | -5% |
Operating Income | 101.1MM | -53% |
Operating Expenses | 460.8MM | +5% |
Net Income | 146.4MM | -43% |
R&D | 141.5MM | +4% |
G&A | 319.3MM | +4% |
Amortization | - | - |
Interest Expense | 4.6MM | -6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Dexcom stock shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.
QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.
DexCom, Inc. (NASDAQ:DXCM) Q1 2024 Earnings Call Transcript April 25, 2024 DexCom, Inc. beats earnings expectations. Reported EPS is $0.32, expectations were $0.27. DexCom, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to the Dexcom […]
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom ( NASDAQ:DXCM ) First Quarter 2024 Results Key Financial Results Revenue: US$921.0m (up 24% from 1Q 2023). Net...
Dexcom stock plunged Friday after the company raised its sales outlook for the year, but not enough to satisfy investors.